is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The CPhI Festival of Pharma welcomed specialist speakers from industry-leading pharma companies to share their insight and expertise as part of its 10-day online content programme, dedicated to the new challenges that the industry is currently facing.
Medicines for Europe
Adrian van den Hoven, Director General, Medicines for Europe Adrian van den Hoven joined Medicines for Europe as a Director General in September 2013. His priorities at Medicines for Europe are to stimulate competition in off-patent medicine markets, to foster market access for generic, biosimilar and value added medicines, to support policy measures for sustainable pricing, to promote high regulatory standards while ensuring that the associated costs can be integrated into market dynamics and to develop a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value added medicines industries. Prior to joining Medicines for Europe, Adrian van den Hoven was Deputy-Director General of BUSINESSEUROPE where he was responsible for the International Relations department, covering trade negotiations and bilateral relations, and the Industry department, covering industrial, energy, environmental and research policy. He previously worked as an International Relations researcher and an adjunct professor in Italy (EUI), France (Nice) and Canada (Windsor). He obtained his doctorate in Political Science from the University of Nice, France in 2000.
Aimad Torqui is Director of Global Regulatory Policy at MSD. He has worked with governments, regulators, trade bodies and other external stakeholders to shape robust science-based regulatory policy. Previous employment included various positions with the Netherlands regulatory agency - Medicines Evaluation Board.
West Pharmaceutical Services
Dr Alex Lyness joined West in 2016 as Manager, Research & Technology and is based at the Global Headquarters in Exton, PA. He leads the front-end research for the company evaluating new containment and delivery technologies, such as those required to cryopreserve and administer cell and gene therapies. To achieve this, Alex leads a dynamic interdisciplinary research team that collaborate internationally with high-calibre academic institutions and early-stage companies. Alex gained his PhD in Mechanical Engineering from Loughborough University, UK, whilst also working at a biotech start-up based in Oxford, UK. Alex is a Chartered Engineer with the Institution of Mechanical Engineers.
Alise Cortez and Associates
Dr. Alise Cortez is a Chief Purpose Officer, Management Consultant, Inspirational Speaker, Author, Radio Host, and Social Scientist based in Dallas, Texas. Having developed her expertise within the Human Capital / Organizational Excellence industry over the last 20 years, today she is focused on enabling organizations to lead from purpose and create cultures anchored in meaning that inspire impassioned performance, and meaningful engagement and fulfilment, while encouraging a devoted stay within the organization. For individuals, she also facilitates an online Catch Fire global community and various retreats to enable people hungry for a more meaningful and purposeful life to create it for themselves. Her radio program Working on Purpose is a thought leadership series to steward a future where people are passionate about their work, inspirational leadership helps team members realize their greatness, and capitalism thrives while serving the highest causes. Alise is the author of the book, Purpose Ignited: How Inspirational Leaders Unleash Passion and Elevate Cause and curator of Passionately Striving in Why: Women Who Persevere Mightily to Live Their Purpose, both due out in late 2020.
King Saud University
Aliyah Almomen received her B.S in Pharmaceutical Sciences in 2005 from King SaudUniversity, Riyadh KSA. In 2010, she joined Janat-Amsbury’s lab at the in the Department ofGynecology- Oncology at the University of Utah Hospital and Clinics, as a Graduate ResearchAssistant and received her Doctor of Philosophy (Ph.D.) in Pharmaceutics and Pharmaceutical Chemistry in 2016. Her supervisory PhD committee included Professor Hamid Ghandehari,Professor You Han Bae, professor James Herron, and Dr. Paul Summers. Her research interestsfocus on providing a better and optimized therapy for gynecological cancer through the developmentof new drug delivery system and constructing reliable animal models. Currently, she works as anAssistance Professor in the Department of Pharmaceutical Chemistry, King Saud University,Riyadh Saudi Arabia.
FabRx - University College London
Alvaro is co-founder and Development Director at FabRx, the first company focused on developing 3D printing technology for fabrication of personalised medicines and medical devices. He is also honorary lecturer at University College London - School of Pharmacy (UK) and part-time lecturer at the Faculty of Pharmacy - University of Santiago de Compostela (Spain). Alvaro is one of the first researchers to evaluate the opportunities of 3D printing using new 3D printing technologies to manufacture oral dosage forms and medical devices. Alvaro has published more than 48 articles. He has been distinguished as Highly Cited Researcher 2019 from Web of Science and is a recognized world expert in 3D printing of medicines with more than 100 communications to international conferences. He holds a PhD in Pharmaceutics from University of Santiago de Compostela (Spain) and he worked for 3 years as a Registered Pharmacist, thus has first-hand knowledge of the needs in terms of medicines in the community pharmacy.
DuPont Nutrition & Biosciences
Amina is a highly effective senior leader with several years of experience in leadership, generating business growth thru building highly performing technical teams, technology expertise and creating value for customers utilizing business acumen.
Amina earned a Ph.D. degree in Pharmaceutical Sciences from school of Pharmacy, University de la Mediterranean France. She has over 15 years of Healthcare industry experience and have worked for several pharmaceutical and chemical companies.
She joined The Dow Chemical Company in Switzerland in 2011 as a Pharma application specialist to support the business growth in EMEA, and then she moved into leadership role within R&D organization. Since April 2018, Amina is leading the DuPont Pharma Solutions application development & innovation team, and one of her main responsibilities is to build, develop and lead high performing global team for high impact on business growth and value creation in the market.
She is an executive board member of the International Pharmaceutical Excipients Council in Europe, a lecturer at Zurich Federal Institute of Technology (ETH) and chairs the DuPont N&B global diversity equity & inclusion steering committee.
Ana Céspedes is Chief Operating Officer at IAVI, providing oversight and strategic direction to address the operational needs of the organization.
Prior to joining IAVI, Céspedes held several roles at Merck KGaA, most recently serving as global head of strategy and engagement, government, and public affairs. Céspedes founded and led the global market access and pricing function for the company and worked with stakeholders to communicate the clinical, economic, and societal value of innovative medicines. Previously, Céspedes led the first integrated corporate affairs group at Serono Iberia and Merck Spain, was managing director of the Spanish branch of the company’s nonprofit organization, and worked as a senior consultant at Arthur Andersen.
She holds a B.S. and a Pharm.D. from the Complutense University of Madrid, and an MBA from IESE Business School.
Andrew Teasdale PhD has over 25 years’ experience in the pharmaceutical industry as an analytical chemist and within quality assurance and regulatory roles. In his current role he chairs AstraZeneca’s Impurity Advisory Group. Dr Teasdale has published a number of papers relating to mutagenic impurities, and other impurity related matters. He has also advanced a number of key scientific advancements in the control of impurities as the inventor of the purge factor concept . With over 50 scientific papers, he has also written 2 books: Genotoxic Impurities – Strategies for Identification and control. Editor A Teasdale. Publisher Wiley. ISBN 978-0-470-49919-1 ICH Quality Guidelines – An Implementation Guide. Editors A Teasdale, D Elder, R W Nims. Publisher Wiley. ISBN 978-1-118-97111-6
Kemiex AG, Switzerland
Dr. André Rieks has over 20 years of experience as an international tech transfer and quality assurance manager. He is a certified Qualified Person and Third-Party Auditor according to ICH Q7 specializing in APIs, biopharmaceuticals and fine chemicals. Kemiex is an awarded and GDP certified trade & information platform for APIs, food and feed additives.
Thermo Fisher Scientific
Dr. Kane has more than 25 years of experience in the science and business of taking molecules through the entire drug development process. His extensive knowledge spans early stage development to scale-up and commercial manufacturing, and includes technical transfers between global sites and drug life cycle management. Dr. Kane received his Bachelors, Masters and Ph.D. degrees from the Bombay College of Pharmacy, University of Bombay, India, and served as a post-doctoral fellow at the School of Pharmacy, University of Cincinnati, Ohio. He has also earned an executive MBA from Richard Ivey School of Business, University of Western Ontario, Canada. Dr. Kane is a member of various international pharmaceutical professional organizations, and is often asked to speak about scientific topics on formulation, technology other technical aspects, QbD, etc at major industry events. He has also published many articles in International journals and delivered many talks at meetings and conferences cross the globe.
Anne-Lise Ducournau Lichtenberg graduated as a Pharmacist from University Paris V in France and holds an MBA and a Master degree in Healthcare system policy. Having worked in public and private settings in Europe and in the US, she brings a broad overview of the pharmaceutical world. With 15 years corporate project management experience in the pharmaceutical and OTC industry leading cross functional teams to develop new products she strives when she can impact people and patient’s life. A firm believer that patient engagement is vital to developing relevant products and services, she is an independent contributor to PFMD (Patient Focused Medicine Development) on the topic of patient engagement.
Informa Pharma Intelligence
Dr. Siu (PhD, MBA, Principal Consultant, Pharma Intelligence | Informa) was an Associate Professor at the Chinese Academy of Sciences, a Visiting Scientist at the National Cancer Institute of the National Institutes of Health, and an Research Assistant Professor at the State Key Laboratory of the University of Hong Kong. She was in-charge and participated in several drug research and development projects sponsored by the Ministry of Science and Technology of the People's Republic of China, the National Natural Science Foundation of China, local governments, multinational pharmaceutical companies, and Chinese Biotech companies. She has served as a postgraduate students’ supervisors and a member of the American Association for Cancer Research (AACR). She has published more than thirty papers in international scientific journals. After receiving a first-class Honors Bachelor and Ph.D. degrees, she carried out the postdoctoral fellow research at the University of Hong Kong and later obtained an MBA from the Hong Kong University of Science and Technology Business School. She was the invited speakers in CPhI China 2019, 2020, ChinaBio® Partnering Forum 2018, Changjiang Securities 2018 Investment Strategy Summit, China Pharmaceutical Industry Association: 2018 Investment and Financing Summit, etc.
CPA (Chemical Pharmaceutical Association) - Chemsafe
Huhtamaki Flexible Packaging
Armin Ullmann is Product Manager Sustainable Healthcare Laminates at Huhtamaki Flexible Packaging Europe. With his team he is responsible for all sustainable and recyclable developments and projects of flexible barrier laminates for the Healthcare market. With almost ten years of experience in developing solutions for customers in various fields of packaging applications, the business engineer is focusing on providing dedicated solutions, with a good mix of commercial focus and technical complexity.
Asmita Khanolkar has a Master’s degree in Material Science & Engineering. With 24 years of manufacturing experience specializing in the Medical Device and Pharmaceutical Services industry, she has managed various device projects from concept to commercial launch. Her product portfolio includes single use, wearable, implantable drug/biologic/device combination devices for drug delivery, diabetes management, cell therapy, and biotech/pharmaceutical markets. She has held various engineering and management roles in New Product Development, Manufacturing Engineering, Advanced Quality Planning, Operations, Supply Chain and Product Life Cycle Management. Her current responsibilities include pharmaceutical services strategy and commercialization of innovative technology platforms for drug delivery and fill finish combination products. Asmita has presented at various medical device and healthcare conferences and served on the advisory board .
University College London
Atheer received her Bachelor’s degree in Pharmacy in 2015. She then pursued anMSc in Pharmaceutics at the UCL School of Pharmacy, University College ofLondon, where her research was aimed at exploring the potential of 3D printing forthe preparation of medicines. Currently, she is pursuing a PhD in Pharmaceutics atthe same institution where her research is focused on fabricating drug deliverysystems and implantable devices using 3D printing. Her research has allowed her toexplore a multitude of 3D printing technologies for different pharmaceuticalapplications, making her one of the pioneers in this area.
Mankind Pharma Limited
With around 22 years experience in the Indian Pharma Industry, Atish Majumdar is currently President at Mankind Pharma and responsible for Mankind Pharma’s Specialty Businesses. Prior to Mankind, he has worked at Lupin. A management graduate from Amity Business School, he joined Lupin from Campus as an MT grew through the ranks to be a Vice President and Cluster Head. A believer in the transformational power of digital interventions and people development; Over a career of 22 years, he has successfully initiated, executed and have driven various digital and people interventional strategies which has helped transform processes, outlooks and business outcomes in the organisations where he has worked.
European Thought Leadership - IQVIA
Aurelio creates topical and forward-looking strategic content relevant to pharma executives worldwide and publishes articles, blogs and white papers on a regular basis. Aurelio’s predominant focus is on off-patent markets where he generates evidence-led insights with a view to spark high-level discourse on biosimilars, generics and value added medicines. Moreover, he is involved in numerous projects exploring the interface between healthcare and digital technology. He is considered a subject matter expert in these areas and speaks at numerous conferences worldwide, presents at board-level meetings and engages in consulting projects.
College of Pharmacy, King Saud University
Prof. Aws Alshamsan is the Dean of the College of Pharmacy at King Saud University and Editor in Chief of the Saudi Pharmaceutical Journal. He is Ex-SFDA Consultant (5 years) for Biologics, Biosimilars, Vaccines, and ATMPs. His administrative and managerial experience included the following positions: Director of the Research Center at the College of Pharmacy, KSU (2012-2013), Co-Director of Joint Center of Excellence in Nanomedicine at KACST (2013-2015), Director of King Abdullah Institute for Nanotechnology (2014-2017), and Dean of the College of Pharmacy, KSU (2017 to date). He received his PhD in Pharmaceutical Sciences (with specialization in NanoBiotechnology) from the University of Alberta, Canada in 2010. He worked in the development of cancer vaccine for NSCLC owned by MSD under the name STIMUVAX®. He worked as a postdoctoral fellow at the National Institute for Nanotechnology, National Research Council (NINT-NRC) in Canada, then he was given a Visiting Professor status immediately afterwards. He heads and participates in many committees. He published over 60 publications, book chapters, and patents, and he received several awards including the Gattefossé Canada CSPS Award in Lipid-Based Drug Delivery.
Aptar CSP Technologies
Badre Hammond, MBA is Vice President, Commercial Operations at Aptar CSP Technologies.
Badre’s background is in Biochemistry and drug development, with 16 years’ experience in pharmaceutical product development, packaging and drug delivery systems. Badre has broad experience in managing development of novel drug product programs for the pharmaceutical market, from formulation development, through pre-clinical and CMC, all the way to market launch. As the VP of Commercial Operations for Aptar CSP Technologies, his current focus is on commercial best practices, strategy and business development.
American Chemical Society
Dr Bibiana Campos Seijo is the Editor in Chief of Chemical and Engineering News (C&EN) and vicepresident of the C&EN Media Group. C&EN is the news organization of the American Chemical Society, one of the largest scientific societies in the world.
C&EN is the world's most comprehensive and authoritative news source about chemistry and related fields, providing coverage on a broad spectrum of topics, including research advances, business and policy trends, chemical safety practices, career guidance, and more.
Since Dr Campos Seijo took the helm of C&EN at the end of 2014, the Group has undergone a significant transformation, from a news organization centered around a lauded but niche print publication to a global, multichannel media brand. Under her leadership, C&EN has received a number of accolades and awards recognizing its editorial leadership, design, multimedia products, innovative culture and more.
Dr Campos Seijo holds a BSc in Chemistry from the University of Santiago de Compostela in Spain and a PhD in Chemistry by the Manchester Metropolitan University in the UK.
Bikash has over 30 years of experience in design and development of pharmaceutical, biotechnology, medical device and IVD products. He has successfully commercialized over a dozen products in his career. Bikash has held senior management positions in several firms prior to joining Pharmatech. He is a certified Lead Assessor and Lean Six Sigma Master Black Belt and a frequent speaker at industry conferences.
He is a member of the USP National Advisory Committee for API's and Excipients, LSIT Technical Advisory Board and The Stem Cell Partnering Advisory Board. Bikash currently provides recurring editorials to both Pharmaceutical Manufacturing and Controlled Environments magazine as an industry thought leader and is a member of their editorial advisory board. He is a member of CPhI's Expert Industry Panel and a member of the RFID Alliance with expertise in the effective application of security and RFID in the pharmaceutical supply chain. He has designed and built biotech facilities globally and has established global supply chain frameworks for both large and small organizations. He holds a BS in Biochemistry from University of California San Diego and a BS in Chemical Engineering from University of California San Diego.
Dr Boliang Gong has a Ph.D. in molecular biology. He has been engaged in the field of microorganism and biological products and is mainly responsible for the development, production and quality control of biopharmaceutical and traditional Chinese medicine genetic engineering technology. Nowadays, he is engaged in the field of technology and management of pharmaceutical packaging materials, mainly responsible for developing pharmaceutical ophthalmic drug packaging, spray pumps, nasal spray pumps and other packaging products.
Bornadata (Bonnie) Bain, PhD, is the Global Head and EVP of Healthcare Operations and Strategy at GlobalData. Bonnie has almost 20 years’ experience in the healthcare sector and a proven track record of developing innovative solutions on both the client and agency sides of the business. Bonnie was GlobalData Healthcare’s first western analyst and under her leadership, the company launched a number of premium syndicated reports, analytical tools and databases in the pharmaceuticals and medical devices space. Prior to GlobalData, Bonnie was Vice President and Global Research & Analysis Director for Informa’s PharmaDivision, which includes Datamonitor Healthcare, Scrip Group, and Business Insight. Bonnie also worked for several years at Decision Resources as an Analyst and Project Manager. On the client side of the industry, Bonnie worked for several years as a Senior Manager in Marketing Strategy and Analytics at Boston Scientific where her work contributed to the successful commercialization of the first ever Access and Visualization Platform at the company. Bonnie has a PhD in Biochemistry and Molecular Biology from Purdue University and completed a Post-Doctoral Fellowship in Molecular Pharmacology at the University Of Miami School Of Medicine.
University of Pennsylvania
Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. He received a B.A. (Biology) from Penn and a Ph.D. in Immunology and Infectious Diseases from Johns Hopkins. First-in-human adoptive immunotherapy trials include the first use of a lentiviral vector, the first infusions of gene edited cells, and the first use of lentivirally-modified cells to treat cancer. Dr. Levine has overseen the production, testing and release of 3,000 cellular products administered to >1,200 patients in clinical trials since 1996. He is co-inventor of the first FDA approved gene therapy (Kymriah), chimeric antigen receptor T cells for leukemia and lymphoma, licensed to Novartis. Dr. Levine is co-inventor on 27 issued US patents and co-author of >180 manuscripts and book chapters with a Google Scholar citation h-index of 86. He is a Co-Founder of Tmunity Therapeutics, a spinout of the University of Pennsylvania. Dr. Levine is a recipient of the William Osler Patient Oriented Research Award, the Wallace H. Coulter Award for Healthcare Innovation, serves as President of the International Society for Cell and Gene Therapy, and serves on the Board of Directors of the Alliance for Regenerative Medicine. He has written for Scientific American and Wired and has been interviewed by the NY Times, Wall Street Journal, Washington Post, NPR, Time Magazine, National Geographic, Bloomberg, Forbes, BBC, and other international media outlets.
Caroline is the Global Quality Audit Regional Hub Director for Asia Pacific and Japan based in Osaka, Japan. She is responsible for managing the Asia Pacific team, as well as conducting audits of AstraZeneca manufacturing sites, contractors, suppliers, due diligence and other audits where specialized expert technical skills and experience are needed. Previously she was the Director of Operations Compliance, where her responsibilities included developing and leading the implementation of the Compliance strategy in Global Operations and Supply Chain; ensuring the deployment of an effective compliance program for Operations including Responsible Sourcing; accountability for the external audit program. In addition, she is an experienced Safety, Health and Environment professional undertaking sites audits for both internal and external supply network. In early 2018, I became the lead representative for PSCI for AstraZeneca, further allowing me to build on the strong working relationships with other PSCI members, including members of the Board. The insights gained have consolidated my belief in setting Industry-wide expectations of our supply chain (both internal and external networks) and in challenging future state. Through the existing and previous Boards, I have seen increased momentum both in strategic direction, pace and both internal and external engagement to move our organisation forward as a lead player in supporting Ethical and Responsible Sourcing in the Pharma Sector. I believe that as an organisation we have the potential to do even more, and that we can leverage the broader mindset of Sustainability to drive both value and increased reputation in our sector.
Catherine Hanley is the Vice President and Head of Marketing & Customer Experience for Emergent BioSolutions’ Contract Development and Manufacturing (CDMO) business unit and the leader behind Emergent’s CDMO brand development and awareness. Integral to her function are the key marketing pillars of the brand including thought leadership, digital/inbound marketing, strategy, distribution, and implementation of traditional and innovative multi-channel marketing initiatives.
In alignment with Emergent’s corporate brand, Catherine and her team execute the latest multi-channel, inbound, and digital marketing strategies to drive internal/ external thought leadership, brand awareness and lead generation, along with a harmonized customer experience. Superior customer service is obtained in part through clear understanding of client needs.
Prior to joining Emergent BioSolutions, Catherine spent 14 years in the CDMO industry in marketing, business development, and operations at companies including Cambrex, Lonza, and Alcami Corporation. Catherine also has hands-on laboratory experience in biologics, and most recently served as the head of marketing and corporate communications at Alcami Corporation. Catherine holds a Bachelor of Arts degree from Franklin & Marshall College and an MBA from the University of Maryland, Robert H. Smith School of Business.
Compassion and empathy are important, not only when working with clients, but when working within your own team. Catherine leads with empathy and integrity and has a proven track record of developing high-performing and highly motivated teams.
Novo Nordisk Pharmatech A/S
Chantale Julien has a current position as Global Product Manager for Quaternary Ammonium Compounds (Quats) for use as APIs and excipients. Ms. Julien has a Masters degree in Life Sciences from Université Laval, Québec, Canada. She has experience from the food and pharmaceutical industries and has been working in the pharmaceutical industry for Novo Nordisk since 2006. Previous work experiences count the Canadian Food Inspection Agency, Chr. Hansen A/S and William Cook Europe.
USV Private Limited
Dr. Doshi has 25 years of professional experience, with more than 10 years of experience at leadership positions managing generics research and development. Over the years, he has established himself as an expert in driving change and bringing positive change to the culture of the company and its workforce. Dr. Doshi is a senior strategic and technical leader with experience in leveraging technical and business acumen to drive generic product development for regulated and non-regulated markets. He is an expert in portfolio identification/rationalization, product development and process development using Quality-by-Design (QbD) concepts Dr. Doshi has been with USV Private Limited. Prior to USV, Dr. Doshi has worked for Apotex Inc at their Toronto location Dr. Doshi has also worked for Sandoz Inc.
W. R. Grace
Chintan Shah leads the global Pharma Technical Customer Service team at W. R. Grace. With about 15 years of work experience in pharmaceutical formulations and working closely with customers across the globe, Mr. Shah has developed a deep understanding of challenges associated with product formulations and providing solutions to resolve these challenges. Prior to Grace, Mr. Shah worked at Innophos Inc., Valeant Pharmaceuticals (Bausch and Lomb), Guardian Drug Company and Nostrum labs. He earned his M.S in Industrial Pharmacy from St. John University, New York and his Pharmacy degree from Rajiv Gandhi University, Bangalore, India.
Chris Rojewski is an Associate Director of Regulatory Affairs within the GRA HBU organization that is dedicated to supporting the Pfizer CentreOne business. Over the past 4 years, Chris has led the Regulatory Affairs team that is focused on developing a harmonized RA support structure that spans across the Pfizer CentreOne manufacturing network to add to a consistent customer experience. He is also focused on developing internal RA processes to add efficiencies in working with clients. Additionally, he is often leveraged to address Regulatory Affairs needs on client projects that require an official interpretation of a published regulatory guidance.Prior to joining Pfizer, Chris spent 22 years in the Pharma Industry (Baxter Healthcare, Takeda, TAP, and Abbott Laboratories) in leadership roles that span CMC Technical and Regulatory responsibilities. A couple of key accomplishments during this time included his development of a commercial trade dress determination process between R&D and the Marketing teams and the spearheading of the development of a forensic testing program for commercial products (for anti-counterfeiting). Chris’ educational background in Chemistry, and early career responsibilities as an analytical bench chemist, has facilitated his growth as the CMC Regulatory expert he is today.
Christina Hertel is Senior Program Manager for Gold Track, an EIT Health funded Accelerator program. In this role, she leads the identification of visionary, emerging European companies in the healthcare space, that has the potential to massive scale, and within Gold Track, pair them with world-leading expertise to offer tailored strategic advice with operational implementation and business support, that guides a company to make the right decisions towards success. Christina brings over +10 years of international experience in operational and scientific management and has been working in the industry in both venture creation in the biotech industry and venture capital scene. She holds a PhD in Biochemistry, from the LMU Munich and a Master degree in Molecular Biology from Aarhus University.
Claudia Palme is a Senior Executive Advisor in the Pharma and Life Sciences Practice for Strategy&, PwC’s strategy consulting business. Based in Munich, she is advising clients in the pharmaceutical, biotech and medical technology industries across Europe, the Middle East and Africa. Her engagement focuses on commercial evolution and new business models, emerging markets’ expansion, market access and M&A advisory.
Claudia returned to Strategy& after nine years, during which she pursued an entrepreneurial opportunity at her own consulting firm in Dubai and held various senior management positions in the pharmaceutical industry. She can rely on more than 20 years of consulting and corporate management experience in the EMEA region, the U.S. and Mexico.
She is the author of several papers on German health care reform as well as a number of editorials on the MEA region and co-published a book on policy reforms in Germany. In addition, Claudia is a regular speaker at international forums of the health community.
Claudia holds a master’s degree in Public Administration from Harvard Kennedy School of Government and a master’s degree in Economics from LMU Munich.
Corinne Ondo leads the sourcing strategy of glass primary containers for Merck Healthcare and through her team, she also coordinates the procurement of secondary packaging activities for various manufacturing sites in Europe and Latin America. Before joining Merck in 2015, she had over 20 years of international experience in the luxury business, consumer goods, automotive and oil & gas industries. She is an engineer, graduated from French ESIGELEC Graduate School of Engineering.
Catalent Pharma Solutions
Cornell Stamoran serves as Vice President of Strategy & Corporate Development for Catalent Pharma Solutions, the leading global provider of development solutions and advanced delivery technologies for drugs, biologics, and consumer health products. He has spent nearly 30 years engaged with the health care industry, including more than 25 years in advanced drug and biologic delivery and outsourcing. In 2012, Dr. Stamoran founded the Catalent Applied Drug Delivery Institute, whose mission is to educate and advocate for the enhanced use of drug delivery technologies to improve patient outcomes. Cornell has gained frontline experience on the realities of patient adherence and outcomes enhancement, from direct engagement with retail and hospital pharmacists; medical professionals; specialty pharmacies and clinics; PBMs; and payors. Cornell has directly participated in the development of drug design-enabled adherence and outcomes enhancement strategies for more than 150 branded drugs over the last 10 years. He holds several professional certifications, and is a graduate of the University of Michigan.
Zhejiang Langhua Pharmaceutical Co., Ltd
Cynthia has over 25 years of experience in global marketing and CDMO business in pharmaceutical field. She has sucessfully participated and witnessed over 20 NCEs from lab to plant by now. Basing on end to end service, driven by technology and innovation, she has led Langhua Pharma to become one of the top CDMO supplier in China and Nuobai Pharm to provide a one-stop solution to pharmaceutical sourcing and marketing in all over the world with reliability, flexibility and efficiency.
She is also a VP member of China Chamber of Commerce for Import and Export of Medicines and Health Products. She has a grand perspective on chinese pharmaceutical industry. She holds a BS in Pharmaceutical Engineering from Shenyang Pharmaceutical University and an EMBA from China Europe International Business School.
Cynthia Davis is the CEO/Founder of BAME Recruitment and Co-founder of Diversifying.io.
As a multi award-winning CEO, motivational speaker and diversity and inclusion specialist, Cynthia is passionate about improving equal opportunities for people from all walks of life. Cynthia is a mentor to young adults via the Stephen Lawrence Trust Mentorship Programme and a fellow of St Georges College Leadership Fellowship. She is Chair of the Board for Pop Up, a social enterprise working in collaboration with educational, literary and cultural organisations to enable children, empower teachers and engage families from all backgrounds to read more widely and creatively.
Cynthia champions diversity in all areas of her life and has made huge strides in diversifying recruitment, to the benefit of employers and employees alike.
Johnson & Johnson
Dr. Caldwell has extensive experience in toxicology, environmental science, sustainability and risk assessment. He is a founding member of the NSF Water and Environmental Technology Center at Temple University and has been conducting research on pharmaceuticals in the environment and antimicrobial resistance (PIE/AMR) for over 10 years. He is a member of the PSCI PIE/AMR subcommittee and the AESGP environmental experts group. Dr. Caldwell is a Diplomate of the American Board of Toxicology (DABT) and Certified Industrial Hygienist (CIH) and has authored over 30 scientific and technical publications.
Daniel has a decade of experience as an analyst in the biopharma industry, spanning roles in drug discovery, market analysis, competitive intelligence, and strategic consulting. He now develops and leads Informa Pharma Intelligence’s thought leadership program, producing materials that help clients across a range of hot topics in the biopharma industry, most recently including COVID-19, immuno-oncology, tumor-agnostic drug development, artificial intelligence and M&A. As part of this, Daniel regularly participates in webinars, conferences and other speaking arrangements, and he is featured across leading publications such as Nature Reviews Drug Discovery, Scientific American, Scrip, In Vivo and Vice. Prior to joining Informa, Daniel worked as a medicinal chemist at the UK biotech company Summit Therapeutics and graduated with First Class Honours in Natural Sciences from the University of Bath.
Dave Meyers is the National Director for the Life Sciences Industry in the U.S. Health and Life Sciences group at Microsoft. He is focused on strategy, business development, and managing the portfolio of solutions in pharmaceuticals, medical devices and precision medicine – collaborating with partners and customers to transform their health business. He is passionate about the promise of artificial intelligence, machine learning and genomics and accelerating their impact in healthcare and on individuals’ health. He joined Microsoft in 1997 - held various technical, program management, and product development positions. He is a graduate from University of Washington’s Foster School of Business and the Public Sector-Healthcare Program from The London Business School and the Genetics and Genomics Program at Stanford University.
Dean Calhoun is an American Board of Industrial Hygiene Certified Industrial Hygienist (CIH). He has been an environmental health and safety professional for over 31 years.
Prior to starting Affygility Solutions, Dean was the Associate Director of Environmental Health and Safety for Gilead Sciences, Inc., a biopharmaceutical company focused on developing pharmaceuticals for infectious, viral, and oncology applications. His experiences including development and implementation of global EHS guidelines, implementation and coordination of an executive management EHS Steering Committee, establishment of occupational exposure limits for pharmaceutical active ingredients, industrial hygiene program management, and EH&S auditing of research, manufacturing and contract manufacturing facilities.
Dean has spoken for several professional organizations including the U.S. Environment Protection Agency, the Colorado Safety Association, the Bay Area Environmental Safety Group, the National Association for Environmental Management, the National Safety Council, the Occupational Safety and Health Administration, and the American Industrial Hygiene Association.
Dean has also presented at the HPAPI 2012 and 2013 conferences in Philadelphia, PA, and at the High Potent Drugs 2013 conference in Mumbai, India.
He is a member of AIHA, ASSE, and NAEM.
Dr. Reddy's Laboratories
Deepak Sapra is the Global Head of PSAI (Custom Pharma Services and Active Ingredients) business. He is a part of the Management Council of Dr. Reddy’s. Deepak joined Dr. Reddy’s in 2003 from IIM Bangalore campus and has worked in various roles in Marketing, Sales, Business Development and Portfolio, covering most major markets across the world. He has led key projects on several organizational initiatives around market opening and building new businesses. In the recent months, he played a key role in Dr. Reddy's response to COVID-19.
Deepak’s education is in engineering and management. Prior to Dr. Reddy’s, he worked in the Indian Railway Services. He has been a Fulbright fellow and a Chevening scholar. His first book was published in 2018. He is also the co-founder of a charitable trust that works for people with disabilities in eastern India.
Deepak is the APAC business head of Lonza’s newly formed business unit for Capsules & Health Ingredients and the company's managing director for India. He has over 30 years of pharma experience in India & Asia Pacific. His time in the industry has given him a deep understanding of various market segments and has allowed him to develop a wide network of contacts in the healthcare and chemical industry. Deepak has been actively involved in setting up greenfield and brownfield (capacity expansion) projects. He has strong leadership skills and proven track record in sales, R&D, pilot plant operations, business development, strategic planning and operations, including P&L management.
Pharmexcil / Nectar Life Sciences Ltd.
Dr. Dinesh Dua Executive Director, M/S Nectar Lifesciences Ltd. India Chairman, Pharmexcil, Ministry of Commerce, Govt. of India, Chairman, CII Regional Committee on Lifesciences, Past Chairman of Confederation of Indian Industry (CII), Chandigarh Council, Member Executive Council, IDMA Dr. Dinesh Dua, is currently the Executive Director of M/S Nectar Life sciences Ltd.-a US$ 450 Mio.(Rs. 3114 Crs.) Niche company in life sciences. Immediately prior to NLL, he was Managing Director of Akorn India Pvt. Ltd.,a 100% subsidiary of US MNC,Akorn Inc., which was a sequel to a very successful 6 year stint at M/S Nectar Lifesciences Ltd. As CEO & Director on Board between 2007 & 2012. Mr. Dua holds a Masters in Business Management (M.B.A.)-1979 batch from Harvard Business School promoted, Indian Institute of Management Ahmedabad. He has over 41 years of professional experience across varied industries in leadership positions such as Healthcare, Pharmaceuticals & Biologicals, Petrochemicals and Consumer goods, having worked in multinational organizations such as Hoechst (Sanofi Aventis), Berger Paints, and large Indian Corporates like Reliance, Jubilant Organosys, Zydus Cadila Healthcare & as President of Wockhardt Ltd’s International & Biotechnology Strategic Business Unit (SBU) He is currently Chairman, Pharmexcil, Ministry of Commerce, Govt. of India, North India Chairman for Regional Committee on Lifesciences for Confederation of Indian Industry (CII) & is also Past Chairman of CII, Chandigarh Council, Member Executive Council, BDMA & is also a visiting faculty to leading & reputed Management institutes in India. Dr. Dua is also Board Member & Director, Club Service, Rotary Club, Chandigarh, India.
Dix worked for Eli Lilly and Company and Evonik Corporation for 30 years and has been an industry consultant for an additional 10 years. His procurement career across multiple manufacturing sites included extensive travel in Asia, Europe, and the US to evaluate hundreds of potential suppliers of raw materials, RSM's, API's, and drug products. Long term supplier relationships and supply agreements were established to manage spend in excess of $50 million/year while generating significant cost savings and cost avoidance. His responsibilities included leading an annual corporate risk assessment of global supply chains and then establishing and managing risk mitigation plans. Dix is a past officer as well as a volunteer for the Drug, Chemical & Associated Technologies Association, Inc. (DCAT).
DongSoo Kang, PhD, is Head of Biosafety Testing Services(BTS) in Samsung Biologics and is in charge of building and expanding biosafety services required for biopharmaceutical manufacturing. Prior to join Samsung Biologics, he had worked for CRO/CDMO industries as in viral clearance/viral vector process development, such as WuXi Advanced Therapies Viral Vector Manufacturing, WuXi Biologics and WuXi AppTec, Philadelphia, USA. He was a founding member to build up WuXi Biologics’ biosafety testing facility in China. Educational background is Protein Biochemistry and Molecular Pharmacology at University of Texas Health Science Center at San Antonio and Kimmel Cancer Center at Thomas Jefferson University.
Informa Pharma Intelligence
Duncan joined Informa in May 2019 and currently holds the position of Director, Custom Intelligence & Analytics. A global expert in biosimilars and the pharmaceutical/biotech space, Duncan is also a well-known speaker and thought-leader with an established reputation within the healthcare markets Informa Pharma Intelligence serves. Duncan has more than 20 years of experience in the pharmaceutical industry, spanning roles in non-clinical and clinical R&D, sales, marketing, medical affairs, strategic consulting and business analysis. Before joining Informa Duncan worked for a global market research agency where he was responsible for all syndicated disease analysis across a wide range of therapy areas, including respiratory, autoimmune, infectious diseases, rare diseases and oncology. Duncan holds a PhD in Microbiology from the University of Kent, and BSc(Hons) in Medical Biochemistry from the University of Surrey.
Sidney Kimmel Cancer Center at Thomas Jefferson University
Edith Peterson Mitchell, MD, MACP, FCPP, is Board Certified in Internal Medicine and Medical Oncology and is Clinical Professor of Medicine and Medical Oncology at Sidney Kimmel Medical College at Thomas Jefferson University and Associate Director for Diversity Programs and Director of the Center to Eliminate Cancer Disparities for Sidney Kimmel Cancer Center at Jefferson.
Dr. Mitchell’s research in breast, colorectal and pancreatic cancers and other GI malignancies involves new drug evaluation and chemotherapy, development of new therapeutic regimens, chemoradiation strategies for combined modality therapy, patient selection criteria and supportive care for patients with gastrointestinal cancer.
Dr. Mitchell served as the 116th President of the National Medical Association, is a member of the American Medical Association, National Medical Association, Aerospace Medical Association, Association of Military Surgeons, Medical Society of Eastern Pennsylvania, ECOG/ACRIN Cancer Research Group, and Radiation Therapy Oncology Group.
Dr. Mitchell is also a retired United States Air Force Brigadier General.
Graduated in Organic Chemistry at the University of Milan, from 1973 to 1977 he was responsible for the organic and pharmaceutical synthesis laboratory of Roussel Maestretti (Hoechst group). Subsequently, after a period of two years at Chimec S.p.A. of Rome as sales manager, from 1979 to 1983 sales manager for Italy, Switzerland and the Balkan countries of Capsugel (Division of Parke Davis USA). From 1983 to 1995 he was a manager at Helsinn SA (Switzerland) with various assignments for the development of his products including Nimesulide (Aulin) and management of the commercial business of the fine chemical production unit located in the Canton of Ticino, with particular reference to productions for third parties and generic active ingredients. Between 1996 and 1998 he carried out various consultancy activities in the chemical and pharmaceutical field including the creation of the company EG, the Italian branch of the German group STADA Arzneimittel AG, of which he was appointed CEO in 1999. He was first elected vice president and then president of Assogenerici since January 2013.
BioPlan Associates, Inc.
Eric Langer, President and Managing Partner, has over 20 years experience in biotechnology and life sciences international marketing, management, market assessment, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He is an experienced biotechnology strategist, marketing practitioner, publisher, and researcher. He has published, edited and authored numerous books, reports, and major studies on topics including: Advances in Biopharmaceutical Technology in China, Advances in Large-scale Biopharmaceutical Manufacturing, Biopharmaceuticals in the US Market, cell culture reports, media, sera, tissue engineering, stem cells, diagnostic products, blood products, genetics, DNA/PCR purification, blood components, and many others. He lectures extensively on marketing, pricing and channel management topics, and teaches at Johns Hopkins University and American University: Biotechnology Marketing, Marketing Management, Services Marketing, Advertising Strategy, and Bioscience Communication. In 1989 he co-founded BioPlan Associates, Inc. He has launched and managed marketing programs for product lines ranging from $500k to $500 million.
National Committee for Pharmaceutical Industries (NCPI) in Saudi Arabia
Faisal Bin Dail is the Chairman of the National Committee for Pharmaceutical Industries (NCPI) in Saudi Arabia, NCPI is the leading association for pharmaceutical manufacturers appointed in this position in March 2018.
Faisal's main task is to make sure that NCPI is on track to meet its objectives and goals of providing patients with the best quality of medicine that is safe, effective and affordable. He has been active in the pharmaceutical industry for almost 20 years, started his career at MSD, and now he is the General Manager at Baxter Company Limited, Saudi Arabia.
Faisal BinDail has a degree in Pharmacy and an MBA from King Saud University and working with different stakeholders in Saudi Arabia to further develop & strengthen the pharma sector in Saudi Arabia.
Korea Health Industry Development Institute (KHIDI)
Feng Tao is a Chinese Principal Consultant in Korea Health Industry Development Institute (KHIDI), which is a government-affiliated institute. He has made meaningful contribution to the entry of Korean pharmaceutical companies into Chinese markets. He’s specialty area is bio pharmaceuticals, biosimilar, chemical pharmaceuticals, IVD, cell therapy, gene therapy and genetic recombination pharmaceutical. Based on his distinctive working experiences and expertise in the healthcare industry, he has expanded
his business field including marketing, business development, Research and
Development and license in & out, etc. He has worked in Novartis in China
Oncology as a Marketing Director for 3 years, in Xian Janssen as a SFE Senior
Manager & Director for 4 years, in BMS as a Region Manager for 7 years and
Roche as a District Manager for 4 years.
Lachman Consultant Services
Frances (Fran) M. Zipp, President & CEO of Lachman Consultant Services, Inc.
Fran Zipp is President & CEO of Lachman Consultant Services, Inc. As an expert in compliance enhancement, she develops program solutions to meet GXP compliance requirements and delivers strategic guidance and direction toward implementation of effective solutions to client needs. Ms. Zipp has extensive experience in the pharmaceutical, biologic and biotechnology industries from R&D through post-market approval. She assists and counsels Senior-level management in areas of Corporate Governance, Corporate Integrity Agreement Compliance, Consent Decree Negotiations and Resolutions, Application Integrity Policy resolution, and Due Diligence evaluations (facilities; products; technologies).
Virginia Commonwealth University
Dr. Frank Gupton is a professor at Virginia Commonwealth University and holds joint appointments in the Departments of Chemistry and the Department of Chemical and Life Science Engineering. He is
the Floyd D. Gottwald Chair of Pharmaceutical Engineering and also serves as Department Chair of the Chemical and Life Science Engineering Department. His thirty-year industrial career centered on the development and commercialization of chemical processes for pharmaceutical applications. Dr. Gupton’s research group is currently focused on the development of continuous
processing technology to facilitate the discovery, development and
commercialization of drug products. Prior to joining the faculty at Virginia
Commonwealth University, Dr. Gupton served as the Executive Director of North
American Process Development for Boehringer Ingelheim Pharmaceuticals and led the commercialization of the widely prescribed HIV drug nevirapine. Dr. Gupton received his Bachelors of Science degree in chemistry from the University of Richmond and graduate degrees in organic chemistry from Georgia Tech and Virginia Commonwealth University.
A biochemical engineer by training (Bordeaux Polytechnic Institute), Frédérique also holds a Master of Business Administration from KEDGE Business School. Frédérique has been working in the pharmaceutical industry for more than 20 years: first at AstraZeneca UK, working on analytical development of therapeutic proteins and antibodies, then at CDMO Bertin Pharma (now Eurofins), working mainly on generic product development and licensing out.Frédérique joined Capsugel® in 2010 as Pharmaceutical Business Development Manager, providing technical and regulatory support for new capsule-based product developments.
Frédérique has developed specific expertise around capsule-based DPI product development and filing, supporting multiple companies in the EMEA and United States by working on innovative products.
Gary started his career in life sciences working on the ground-breaking cloning project “Dolly the Sheep”. Since then, he has held senior executive positions in a number of international biopharmaceutical, CRO and MedTech companies.He joined SGS in 2014 as business manager for the biologics characterization and R&D sites across Europe, then in 2016 was appointed as Global Head of Regulatory and Compliance for the life science segment.
Now Global Head for Life Sciences at SGS since 2018, Gary now leads the business development strategy and growth plan for the integrated network of analytical testing laboratories across North America, Europe and Asia-Pacific.
Joined Bachem in 2015 when American Peptide Company was acquired by Bachem. Worked in peptide API CMO industry for more than 25 years in the areas of sales, marketing, business development, product management, and general management. Member of the board at American peptide company from 2009 to 2015. Current member of the board in Bachem Japan K.K.
Chimica Oggi- Chemistry Today- Pharma Horizon
Experienced Managing Editor with a demonstrated history of working in the publishing industry. Responsible for running the day-to-day operations of TKS Publisher journals. Oversees and supervises all editorial activities of the journals such as the peer review process, article acceptance or rejection, preparing papers for publication, and producing the journal.
Second-in-command, reports directly to the editor-in-chief / managing director. Skilled in Editorial Management, Biological and Chemical Skills, Media Relations, Organization of Scientific Conferences & Webinars, and Journalism. Strong media and communication professional with a Master of Science (M.S.) focused in Agro Food Biotechnology from Università degli Studi di Milano.
Pharma & Biopharma Outsourcing Association
University of Oslo
Dr. Gunnveig Grødeland obtained her Ph.D. in immunology and vaccinology in 2013 from the University of Oslo in Norway. She has since worked at the University of Oslo and Oslo University Hospital, interrupted by a Fulbright Scholarship to The Scripps Research Institute in San Diego. Grødeland is leading her research group on Influenza and Adaptive Immunity, and is also Dep. Director of K.G. Jebsen Centre for Influenza Vaccine Research. Her research interests has focused on development of novel vaccine formats against infectious diseases, and she has brought novel vaccine formats from construction to clinical evaluations.
Hanneke is the only lawyer-pharmacist with a PhD in the Netherlands. Therefore, she is a lawyer with an extraordinary, atypical background. Hanneke specialises in the EU and national regulatory life sciences law. She holds a PhD in pharmacokinetics and pharmacodynamics. Previously, she was an inspector for Clinical Trials and Pharmacovigilance with the Inspectorate for Healthcare (IGJ). This rare background gives her a unique perspective and understanding of the life sciences sector. In her
practice, Hanneke advises life sciences and healthcare clients and litigates
on a wide range of issues. Areas of expertise cover marketing authorisations, reimbursement, compliance, pharmacovigilance, advertising issues, product
liability, issues on the interface of IP and regulatory, and —finally —
regulatory assistance in transactions. For the use of M&A or for the comfort of investors, Hanneke is able to provide tailor-made Transaction Regulatory Compliances prognosis reports. Hanneke is a university lecturer in Leiden and she publishes frequently on regulatory life sciences issues, such
as new European legislation and the impact of recent judgments in the sector.
Healthy Work Company
Heather Beach is the founder and Managing Director of Healthy Work Company. She has been running businesses in the health and safety community for over 20 years.
Having started in information services running the first available health and safety service from HSE on CD-ROM at SilverPlatter – she moved to Barbour and then to Safety & Health Expo, SHP, and IOSH conference.
Heather is a specialist in organisational cultural change and delivers training to large global organisations in better wellbeing, empowering thriving at work.
Heather is the founder of Women in Health and Safety and the Barbour webinar series which attracts over 3000 attendees a month.
Pink Power Moms
Heidi is a sought after inspirational and informative speaker. Sharing her own experiences related to drug deliver and patient centricity, as well as details gleaned from her extensive global network. She speaks on a variety of topics but HOPE is the treat that binds her story together .
Lear how to increase alignment between patients and life science companies from the most important stakeholder - the patient!
A 2 time cancer survivor, Heidi uses her experiences to help others. She has held various Board positions with the the ACS, DOD and other cancer research and support organizations worldwide.
SGS Life Sciences
Ian Cooper took over as CEO of Famar in March 2020, following the acquisition of Famar by the investment funds York Capital Management and Elements Capital Management, leading Famar’s recovery free of any external long term debt. Covid19 has provided Ian and the Famar team with an additional challenge to keep the manufacturing sites fully operational in Spain, Italy and Greece and to keep the Pharma 3PL business in Greece distributing essential medicines. Ian joined Famar in 2012 and has covered various Regional Operations roles, and before his last promotion Ian was Senior Vice President of Commercial Operations and Supply Chain. A Chemical Engineer, Ian has previous experience in the Hygiene products and Food FMCG industry sectors, covering roles in R&D, Plant Management, and Multi-site Technical and Operations leadership. A British citizen, Ian has lived and worked in France, Germany, Italy and Spain, and is currently based in Madrid.
The Tranquil Mind
The world is ever-changing and never more so than during and post COVID. How you and your staff or colleagues cope, especially in these times of change, is key to the ongoing success of your business and wellbeing of each individual. Ian Helps teams find peace in chaos, reducing stress levels, and using brain training to help individuals and teams thrive at work. Ian received his certificate in mindfulness and meditation from The School of Positive Transformation.
American Journal of Endocannabinoid Medicine
Jean-Marc Gilson graduated with a degree in Chemical Engineering from the University of Liège (Belgium) and holds an Executive MBA degree from the IMD in Lausanne (Switzerland). Before joining the Roquette Group, he was Vice-President and Chief Operating Officer at Nusil Technology in California. Previously, he was Executive Vice President at Dow Corning, where he spent 21 years in Belgium, Japan and the United States.Jean-Marc Gilson’s main responsibility is to further accelerate the global growth of Roquette in plant-based ingredients for Food, Nutrition and Pharma markets.
Luminary Therapeutics, Inc.
Jeff is a seasoned CEO with a proven track record at profitably growing emerging companies and business divisions. He has raised over $10M in seed capital from angel investors to start four different companies which he then led to becoming profitable or acquired. At his time at PCT as their COO he supported over 20 clinical trials in the Cell and Gene Therapy field. These trials ranged from Phase I to Phase III pivotal trials.
Former Chief Operating Officer of Progenitor Cell TherapyProcessed over 25 clinical trials for respective therapy customersResponsible for tech transferring Kite’s T-Cell therapy out of the NIH, Novartis’ cell therapy out of U-Penn and Adaptimmume’s cell therapy out of U PennCell processing / manufacturing experience that spans Phase I, II, & III therapies.
Jim Miller advises bio/pharm companies and CDMOs on manufacturing strategy. He is the founder and former president of PharmSource, the pharmaceutical outsourcing industry’s premier collection of market intelligence about contract manufacturing, which is now part of GlobalData. Jim has consulted to many of the top bio/pharmaceutical companies and contract research and manufacturing organizations. He previously served as a consultant in corporate strategy with the Boston Consulting Group and as an executive with several healthcare information companies. He holds an M.B.A. degree from the Stanford University Graduate School of Business.
John Davidson is the Head of Lonza’s largest Capsules & Health Ingredients site in the United States. Trained as an engineer and with unique experience in operations, quality, supply chain and customer service, he has lead the site through a period of unprecedented growth in recent years. John calls upon over 20 years of multi-national experience in the biopharmaceutical and consumer health industries to provide insight for the future of manufacturing in the United States.
Julien Meissonnier serves as Chief Scientific Officer for Catalent Pharma Solutions. Mr. Meissonnier has over 16 years of Global experience in pharmaceutical development. At Catalent, he leads the Global R&D organization providing technical and scientific leadership for the development of delivery systems for poorly soluble and permeable drugs that lead to approvable regulatory dossiers. His responsibilities include early stage screening activities, developing products, scale-up and technology transfer, directing clinical supplies and supporting product launches. Additionally, is a Board Member of Catalent Applied Drug Delivery Institute and served as Board Director of Alsace BioValley innovation cluster. He received his Engineer Degree in Physico-Chemistry from the ENSI in Caen, France.
Dr. Karl Abele has specialized in use and
development of hyphenated MS equipment since 1986 at the Ruhr University in Germany, where he obtained a Ph.D. in chemistry in 1990. He moved to Switzerland in 1990, where worked as MS application specialist for three GC/LC/MS manufacturers. In 2010 he joined Solvias, a Basle based contract
research organization serving pharmaceutical manufacturers worldwide. He is currently leading a group of 15 scientists, performing identification and quantification of impurities in drug products at ultra-trace level, as well as E&L studies. His team is using state-of-art equipment (HRAM-LC/MSMS e.g. ThermoFisher Q-Exactive Systems) in a GMP regulated environment. Dr. Karl Abele and his team have been involved in analytical evaluation of nitrosamines from the start in June 2018 and have continuously improved their methodology and software solutions applied.
GC Legal Services
Katherine Dutmer is an independent legal counsel with over 20 years experience in Life Science Industry with a focus on commercial contracting, intellectual property, governance/regulatory and M&A. Katherine supports clients in healthcare, agri, biotech, food and feed industry for which she acts as company lawyer on an interim basis, fills gaps in legal team’s capacity to deal with adhoc legal matters, joins or leads (legal) projects. Katherine is considered business savvy and has access to an extensive international network. Over the last 10 years Katherine specialized in trade secret protection (companies’ developed knowledge) as tangible asset and missing link in the valuation of companies. Prior to this, Katherine was Global Legal & IP Manager at Enza Zaden and trained attorney with Baker & McKenzie and Hogan Lovells. Katherine holds a law degree from Leiden University and is a frequent speaker at international conferences and Nijenrode Business University
Nelson Labs NV
Kathleen Lava successfully completed her Ph.D. in Chemistry at the University of Leuven (Belgium) in 2012. Afterwards she performed postdoctoral research in the team of Prof. Richard Hoogenboom at Ghent University. In 2016, she started at Nelson Labs Europe as a Study Director for Extractables and Leachables. She is part of the team specialized in Large Volume Parenterals, Ophthalmics and Disposables, with focus on ophthalmic drug products.
Kelsey ACHENBACH joined Roquette as Head of Marketing for Pharmaceuticals beginning of 2017. She has a very diverse background in specialty chemicals and polymers, with a particular focus on healthcare and pharmaceuticals. Over her career, she has transitioned from operations management to commercial management, with a deep expertise in successful project management, strategic planning and implementation, as well as commercial sales and new business development. Thanks to a diversified career, Kelsey has an extensive global management experience.Ms. ACHENBACH holds an MBA from Columbia Business School and London Business School, and she also sits on the DCAT Advisory Council.
Kevin has over 30 years’ experience working in the healthcare sector, principally with pharmaceutical, biotechnology and business consultancy companies. He has been involved in the successful divestment and acquisition of many businesses, acting as advisor to major pharmaceutical and biotechnology companies. During his career Kevin has held senior positions in pharmaceutical research, alliance management, business development and transactions. Prior to Results Healthcare, he worked at Hoechst (Sanofi), Quintiles, Roche Pharmaceuticals, Inpharmatica and
PharmaVentures. Some of Kevin's latest transactions include: GSK’s divestment
of its Mississauga, Ontario manufacturing facility to Bora Pharmaceuticals, Bridgepoint's acquisition of PharmaZell, Hospira, a Pfizer company, on the divestment of its UK compounding business to Baxter, Sanofi's divestment of the Holmes Chapel manufacturing site to Recipharm, Sanofi's divestment of the global rights to LEUKINE® and associated manufacturing assets to Partner Therapeutics.
Dupont Nutrition & Biosciences
Kieran is a highly effective senior leader with over 30 years of working experience with pharma excipients and food ingredients. He is a Chemical Engineer from the Cork Institute of Technology in Cork Ireland and spent close to 28 years with FMC working in manufacturing, supply chain and quality roles. After the acquisition of FMC by DuPont in 2018, he became an integral part of the 'Quality' leadership team at Dupont Nutrition & Biosciences.
In his current role, he drives impactful and strategic initiatives at Pharma Solutions business of DuPont Nutrition & Biosciences by delivering value to create innovative pharmaceutical formulation solutions utilizing the safest, most reliable raw materials for a high-quality product for customers. Kieran has rich cross-regional working experience working at several locations and positions in Europe and the US, primarily in manufacturing and supply chain roles.
Ms Kiran Mazumdar-Shaw is a pioneering biotech entrepreneur, a healthcare visionary, a global influencer and a passionate philanthropist. She is a pioneer of India’s biotech industry and founder of Biocon. She is the proud recipient of two of India's highest civilian honours, the Padma Shri and Padma Bhushan. She has recently been named as the winner of EY World Entrepreneur of the Year™ 2020 Award, which is a testimony to her entrepreneurial journey of over four decades.
FUJIFILM Toyama Co., Ltd.
Koichi Yamada, at Fujifilm Toyama, is the global head of Avigan project. Avigan, favipiravir, is an antiviral drug approved as anti-influenza drug in Japan, and has broad spectrum against RNA viruses.Since the COVID-19 Pandemic occurred, various parties are doing efforts to demonstrate the efficacy of facipiravir against COVID-19 internationally. Recently, Dr Reddy’s and Global Response Aid formulate an agreement with FUJIFILM Toyama to accelerate the clinical development and enlarge the supply capacity. He played a key role in shaping this alliance.
A clinical doctor by background, Dr. Palanivel completed his Master's in International Healthcare Management to explore larger avenues of creating value for patients in healthcare on a global level. He perceives digital health as a medium to champion the cause of
patient centricity and make personalized healthcare an absolute reality. He embraces PatchAi's mission of using state-of-the-art digital technologies to aid the go-to-market time for innovative therapies through the digitilization of clinial studies whilst engaging patients at every step of their care journey.
Kyoung Lim is a senior director of Supply Chain Management at Samsung Biologics, overseeing supply chain activities related to strategic sourcing & procurement, supplier relation management, material planning and logistics. Prior to joining Samsung Biologics, Kyoung held various positions in Procurement, Supply Chain, Project Management, and Product Portfolio , Management at Lonza.
Healthy Work Company
Lauren is an experienced Health and Wellbeing Consultant and trainer, with a track-record of working with leading companies to design, implement and communicate wellbeing strategies that create meaningful change.
Her background as Editor (health, safety and wellbeing) and Head of Training (mental health and wellbeing) has given her a deep understanding of the challenges companies have relating to wellbeing programmes.
Lauren delivers face to face training across the UK in Mental Health First Aid, courses from the shop floor to the board room and train the trainer programmes - as well as webinars globally.
Lauren passionately believes that a focus on wellbeing has a genuine impact on the lives of employees and contributes greatly to business success.
Korea Health Industry Development Institute (KHIDI)
Lee Taylor is a principal consultant in Korea Health Industry Development Institute (KHIDI), which is a government-affiliated institute. He has a wide range of experiences and distinctive profile in the healthcare industry such as bio pharmaceuticals, cosmetic, CMO, etc. He’s major business field is business development, Marketing and license &patent. He has worked as Menarini General Manger for 7 years, Daiichisankyo Sales Force Director for 5 years, Novartis National Sales Manager for 3 years and GSK Area Business Manager for 4 years.
CPA (Chemical Pharmaceutical Association)
Lucia Aleotti graduated with honors in Economics with a thesis on Drug Patent Law.
In June 2001, Lucia Aleotti joined the Board of Directors of A. Menarini srl, parent company of the Menarini Group, together with her brother Alberto Giovanni.
Following the retirement of her father for health reasons, in September 2011 Lucia Aleotti became Vice President and led the company with her brother. In February 2013 she was appointed President serving until June 2018 when Dr. Eric Cornut was nominated.
In 2007 the Regional Council of Tuscany awarded Lucia Aleotti the Silver Banner (Gonfalone d’Argento) in recognition of talented young entrepreneurs.
Currently she is a member of Farmindustria’s Committee of the Presidency and of its Council of Association. She also serves on Confindustria’s Executive Council and General Council.
Lucia Aleotti helded other various positions in pharmaceutical industry associations:
- In Farmindustria (the Italian association of pharmaceutical industries) Lucia Aleotti was Vice President with responsibility for sector’s industrial plan, Member of the Committee of the Presidency and President of the Research Commission;
- In Confindustria, Lucia Aleotti was Member of the Technical Committee for Economic Development, Member of tha European Technical Committee and Member of the Board of Management;
- In EFPIA (the European Federation of Pharmaceutical Industries and Associations) Lucia Aleotti was Member of the Board, Heads of Europe, Member of EU Enlargement Team and Member of the Economic and Social Policy Committee;
- In IFPMA (the International Federation of Pharmaceutical Manufacturers & Associations) she was a Council Member;
- Lucia Aleotti was a member also of the World Biopharmaceutical CEO Roundtable (BCR)
Dr. Boltri is a pharmaceutical chemist by training and completed his degree at the University of Turin, With 30 years of experience in the Pharmaceutical Industry, Dr Boltri has held leading positions as Department Head and Director.
In the current role, he is responsible for identifying new and innovative technologies as well as valuable opportunities for product development and co-development.
Ly has over 20 years of experience in the healthcare and pharmaceutical industry and has extensive experience in market research and analysis. Ly is currently the Director of Commercial Strategy at Informa Pharma Intelligence where she leads the strategy for partnership
opportunities with clients on thought leadership and custom projects. Ly
first joined Informa in 2010 as an analyst at Datamonitor Healthcare, a service within Informa that specializes in in-depth market assessment and drug forecasts. More recently, she led a global analyst and market access team as the Vice President of Disease Analysis and Strategy, and she oversaw the content strategy and thought leadership program as Head of Content Strategy and Thought Leadership. Ly has a PhD in Pharmacology from the University of New South Wales, Sydney, Australia and conducted R&D research at Johnson and Johnson prior to joining Informa.
Syngene International Limited
Dr. Mahesh Bhalgat holds a Ph.D. in Medicinal Chemistry from the University of Utah, the USA, and a bachelor’s degree in Pharmacy from the University of Mumbai. He has over 25 years of experience in both biotechnology and biologics. Dr. Mahesh has worked in different facets of R&D which include analytical development, technology transfer, regulatory sciences and quality. During his career, he has been associated with companies such as Celera Genomics, Molecular Probes, Monsanto and Amgen. Prior to joining Syngene, he was the Chief Operating Officer at Shantha Biotechnics, a Sanofi company, where his responsibilities included operations and long-term strategic planning and development. As Chief Operating Officer and a member of the Executive Committee at Syngene, Dr. Mahesh Bhalgat is responsible for operational efficiency, safety, quality and compliance.
Marie-Liesse Le Corfec, Global Head of Portfolio Marketing, leads global portfolio for pre-fillable pharmaceutical systems at BD. Trained in Business Management at Kedge Business School and Aston University, and in Health Economics and Policy at the London School of Economics, Marie-Liesse has accumulated over 25 years of experience in the pharmaceutical and vaccine industry where she held varied marketing or market access roles at national, regional or global levels. Before joining BD, she specialized in launching
new vaccines and drugs, and successfully expanding the use of in-market brands in diverse therapeutic areas. In companies such as Sanofi, Merck, Novartis or Takeda, she played a pivotal role in 7 major global launches of
vaccines or medicines.
Aspen Oss B.V.
Marieke van Dalen, Aspen Oss B.V., The Netherlands Marieke van Dalen is the global regulatory specialist in the regulatory group dedicated to APIs, with over 30 years of experience in the regulatory field. She is a board member of APIC, the European API Industry organization, and she participates in a number of task forces. She frequently represents APIC in meetings and conferences organized by EMA, EDQM, CPhI etc.
Insight Innovation Center, Nemera
Mark Tunkel is Director of Business Development for Insight Innovation Center Chicago at Nemera. With more than 20 years of global business development experience and a deep understanding of the marketplace challenges and trends impacting the pharmaceutical industry, Mr Tunkel has advised many of the world’s leading companies on their device and product development strategies with an emphasis on driving realization and
the most favorable business outcomes.
Martin VanTrieste is a former chief quality officer at Amgen who was recently named one of Modern Healthcare’s 100 Most Influential People in Healthcare and a leader on The Medicine Maker’s 2020 Power List of Industry Influencers. He brings over 35 years in the industry, with comprehensive experience in
biopharmaceutical manufacturing, quality systems and related government
regulations around the world.
Under Martin’s leadership, Civica has expanded its membership to include over 50 health systems, representing over 1,200 hospitals across the U.S., and secured 40 essential medications for hospitals, eleven of which are being used to treat COVID-19 patients. Most recently, Martin led efforts to deliver 2.1 million vials of Civica medicines to the U.S. Strategic National Stockpile for COVID-19 patient care. In addition to working with quality supplier partners, Martin and the Civica team are working to advance generic drug production in the U.S. and are in the design phase for Civica’s future sterile injectable manufacturing facility.
Prior to joining Civica and Amgen before that, Mr. VanTrieste was with Bayer Healthcare’s Biological Products Division as vice president of worldwide quality and Abbott Laboratories as the vice president of quality assurance for the Hospital Products Division.
Mr. VanTrieste is the founder of Rx-360, an international nonprofit organization that enhances patient safety by increasing security and quality in the biopharmaceutical supply chain. He has also served as the Chairman of the Parenteral Drug Association (PDA) Board of Directors.
Mr. VanTrieste earned a Pharmacy degree from Temple University School of Pharmacy.
Mike Whelan is an Immunologist working as a Project Leader for CEPI (Coalition for Epidemic Preparedness Innovations). His portfolio includes vaccines for Rift Valley Fever, platform technologies and, more recently, COVID-19. CEPI funds the development of vaccines for neglected pathogens with epidemic potential from preclinical development right through to licensure, partnering with both academic and commerical entities. He joined CEPI in December 2017. Mike has over 20 years of industrial biotechnology and 8 years of academic experience. He had his own consultancy company and was formerly R&D director at iQur, (working on VLP based universal influenza vaccines) and the Head of Research at Onyvax Ltd (whole cell vaccines for prostate cancer). Mike is an Honorary Lecturer at the Royal Veterinary College, a fellow of the Royal Society of Biology and has some 40 published papers and 4 patents.
CEO of Bone Therapeutics and visiting Professor at the Lisbon University in Portugal. Member of Alliance for Regenerative Medicine (ARM) Board of Directors. Previously CEO of Zelluna Immunotherapy from 2017 to end of 2019. Chief Commercialization Officer and Chair of the Commercialization Committee of the International Society of Cellular Therapy (ISCT) between 2016 and 2020. From 2006 to 2010 was VP of Global Medical Affairs at UCB. In 2004, joined Nabi Pharmaceuticals as the VP of Clinical, Medical and Regulatory Affairs in Europe. After several clinical, academic and regulatory positions in the public sector in Portugal and at the EMA, spent six years with Bristol-Myers Squibb in various positions including Country Medical Director, Executive Director of Infectious Diseases, Immunology and Dermatology and VP of International Medical Organization in Portugal and Belgium. Holds an M.D. from the Faculty of Medicine of the University of Lisbon, Portugal, and a Ph.D. in Immunology from the University of Birmingham, UK, an accreditation as Specialist in Infectious Diseases and a certificate on Health Economics of Pharmaceuticals and Medical Technologies (HEP). He is Fellow of the Faculty of Pharmaceutical Medicine of the RCP in the UK.
Nicholas Brooke is Founder of The Synergist, which is a collaboration incubator acting as a backbone, providing vision, strategy, stakeholder alignment and execution on multiple international, multi-stakeholder programs aiming to solve significant societal issues. It includes Patient Focused Medicines Development (PFMD), an international collaborative platform dedicated to stimulating innovation in improvement of global health through systematic engagement with patients.
BASF Corporation Pharma Solutions
Nigel Langley, Global Technology Director, BASF Pharma Solutions provides technical support to the pharmaceutical industry and helps solve drug formulation challenges. He has held various senior technical and marketing positions during his 11 years at BASF. Nigel has also worked in Japan and England with Croda International prior to joining BASF. He gained his Chemistry (Hons) degree and PhD (Liquid Crystals) from the University of Hull (UK) and an MBA from Leeds University (UK). He also took a 2 -year Postdoctoral research position at Leeds University (UK) in natural product synthesis. He has over 100 scientific publications and has co-edited 2 books. Nigel is an adjunct professor at the University of Mississippi and a Fellow of the Royal Society of Chemistry (UK). In 2018 he was awarded the Industry Research Achievement Award in Excipient Technology by the IPEC Foundation. He has been a member of the Executive Committee at IPEC Americas since 2010 and is currently Chair Elect. He is also helping to lead the Novel Excipients initiative for IPEC Americas in collaboration with the IQ Pharma Consortium. Nigel is on the Medicine Maker’s Power List for 2020 for small molecules.
Graduated in industrial chemistry in Milan, he started working in Profarmaco in 1971, dealing with engineering and
maintenance, at the factory in Paullo. In the ten years spent in Paullo, he
had the opportunity to learn the various aspects of a company producing
pharmaceutical active ingredients: logistics, scale up of new products from
RD to pilot to commercial production, production planning, introduction of
industrial costs from scratch, purchasing, management control, interaction with the commercial department. In 1982 he became General Manager and CEO and moved to the Milan office, where he also managed sales and administration. In 1989 Profarmaco is sold to the Swedish Nobel Industries, which leaves him in
charge of the company (Profarmaco Nobel) and also entrusts him with the
management of a second company in Italy. In 1991 the Akzo Nobel merger took
place and in 1994 Profarmaco was sold to Cambrex; in Cambrex he continues to
manage the Italian company and is also put in charge of the generics Business
Unit, for the whole group, becoming head of four production units in Europe,
and a member of the group's Executive Committee. In 2008 he became President of Cambrex Profarmaco Milano.
Jefferson Institute for Bioprocessing
Parviz received both his BTech and PhD in Chemical Engineering from the University of Bradford, UK. As a chemical engineer, Parviz combines 37 years of academic and industry experience in bioprocessing with the focus on biopharmaceutical and biologic process development.
As Executive Director for JIB, Parviz leads all of the Institute’s activities including designing and delivering education and training, budgeting and financing, research and development, recruitment, program development, and fundraising for research and future growth.
At the core of Parviz’s philosophy and vision for education is the development and implementation of industry-facing programs to address the growing need for a skilled workforce in biomanufacturing.
Patrick Branch is a Partner in L.E.K.’s Tokyo office and a member of the firm’s Life Sciences practice. He works with businesses and investors in the biopharmaceutical, medical device and broader healthcare sectors. He advises clients on a range of topics, including commercial strategy, corporate and business unit strategy, pricing and market access and M&A.
Patrick joined L.E.K. in 2007 and has worked in the firm’s Tokyo, Singapore, New York and Boston offices. He previously held commercial strategy and business development roles at the Japanese subsidiary of AstraZeneca and the Singapore subsidiary of Biogen. He received a Master of Business Administration from INSEAD and a Master of Public Health from Columbia University. He also holds degrees from the University of London and the University of Nottingham.
International Cannabis and Cannabinoids Institute (ICCI)
Pavel Kubu MD is the expert in the fields of medical informatics and adictology. In 2001, graduated in general medicine with a focus on diseases prevention at Charles University in Prague, 3rd Medical
Faculty. Since 2005 to 2015 worked for Intel Corporation as the Business Development Manager leading projects for Healthcare and Education in Central
and Eastern Europe. In 2006 apointed as chairman of the Ethical Commission of
the National Monitoring Center for Drugs and Drug abuse of the Czech republic goverment. Serves since 2007 as the board member of the Czech National Forum for eHealth where he is focused on research and development of new treatment and preventive methods utilizing eHealth tools for personalised care. 2015 became co-founder of International Cannabis and Cannabinoids Institute which
is focused on clinical research and development of medical cannabis treatment methods, evaluation on quality of cannabis products, CME and development of new care models modulating endocannabinoid system. Americans for Safe Access NGO has elected Dr.Kubu as the board member of this biggest cannabis patient’s organization globaly in 2019. Becoming also the first non-US citizen member of the ASA board.
xCell Strategic Consulting
Peter is the President of xCell Strategic Consulting, a consulting firm to the Pharmaceutical Industry. xCell provides consulting services in the areas of Drug Development, Outsourcing, and Supply Chain. In addition, xCell Provides advice and support for M&A in the Pharmaceutical Services Industry. Prior to founding xCell, Peter served as Division President of Qualitest, Endo Pharmaceutical’s Generic Drug Division. He also served as the President of North America Commercial Operations and CEO at Patheon Pharmaceuticals. Patheon is a leading Contract Manufacturing and Contract Research Organization which at the time was Publicly Traded and had $700 million in revenues and 5000 employees. Prior to joining Patheon, Peter spent 14 years with Wyeth Pharmaceuticals. While at Wyeth, he oversaw a significant portion of the Manufacturing and Supply Chain organization including Consumer Products such as Advil and Centrum Vitamins, Branded Drug Products and Vaccines such as Prevnar. He also oversaw Global Engineering and expansion programs to support drug manufacturing and Research and Development. . Peter also spent 14 years at SmithKline Beecham (now GlaxoSmithKline) before joining Wyeth. His assignments included significant international project work in Europe and the Far East and operations experience with injectable product manufacturing.
Peter is a member of the Global Pharmaceutical Manufacturing Leadership Forum of the ISPE and is a frequent speaker at Industry events. He serves as the Chairman of the Board of Trustees of the Pharma, Biopharma Outsourcing Association (PBOA); a non-profit trade association that represents the needs and interests of Pharmaceutical Contract Development & Manufacturing Organizations (CDMOs). Peter previously served on the Board of IPS – a Global Healthcare Engineering Company, the Board of Frontida Laboratories and the Board of CASA Youth Services – a non profit organization serving the needs of Children in the Foster Care environment. He has a BS in Mechanical Engineering from Villanova University and an MBA from Philadelphia University. Peter and his wife Lynn reside in Valley Forge, Pennsylvania.
Peter Shapiro, PhD, is Senior Director of the Drugs and Business Fundamentals and also serves as the Editor-in-Chief of PharmSource. Peter is a thought leader in Contract Pharmaceutical manufacturing. Prior to joining GlobalData, Peter was at Target Health, a Contract Research Organization (CRO). Peter also worked in small molecule drug development for Abbvie and on in vitro diagnostics at a diagnostic startup. Peter holds a PhD in Molecular and Cellular Biology from the Sackler Institute of New York University and is located in GlobalData’s office in New York City.
Beximco Pharmaceuticals LTD.
Mr. Rabbur Reza, the Chief Operating Officer of the Company, has 24 years of experience in pharmaceutical industry, in the areas of sales, marketing and brand management, international business development, operations management, etc. He had previously worked for Biotech and Milton Pharmaceuticals in Australia. He is also serving as the Managing Director of Nuvista Pharma, a subsidiary of Beximco Pharma. Mr. Reza holds a Bachelor of Pharmacy from Panjab University, India and an MBA from Queensland University of Technology (QUT), Australia. He received executive education in Strategy and Leadership at Harvard Business School, USA and London Business School, UK.
Dr. Reddy's Laboratories Limited
Dr. Rakeshwar Bandichhor is working as a Vice President and Head of Chemistry, API-R&D at Dr. Reddy’s Laboratories, Hyderabad, holds a doctorate in Chemistry from University of Lucknow/University of Regensburg, Germany and worked as Postdoctoral Fellow at University of Regensburg, Germany, University of Pennsylvania and Texas A&M University. He has co-authored more than 170 papers including patents and book chapters published/accepted in various International Journals and contributed to more than 100 academic national and international conferences. He has won various awards and honors in his career; few of them are like Chairman Excellence Award 2010, Best Cost Leadership Award 2010, Anveshan Award 2011, ISCB Award of Appreciation for Industry Scientist 2012, Bharat Jyoti Award 2012 , Roll of Honor Award by Green Chemistry area 2012, Travel grant award, UK 2013, Green Innovation Award 2013 by IGCW-2013, FRSC 2014, CChem 2014, Vice Chair, ACS-India Chapter (South India Section) onwards 2016, CRSI Council member onwards 2017, CRSI Bronze Medal 2018 etc. He was also nominated for Shanti Swaroop Bhatnagar Award for the years 2017 and 2018. He has won STE Green Excellence Award in 2019.
He was invited as a Chief Guest in RSC-DST sponsored Green Chemistry workshop at Delhi University, 2011 and instrumental to organize Catalyst 2013 Symposium featuring Noble Laureate at Dr. Reddy’s. His interview was published in Nature Medicine 2013, 19, 1200-1203, in Process India (February issue 2014) and Business Standards (March 2014). He has also contributed in a concept paper “Reengineering Chemistry” by Tata Strategic Management Group and IGCW-2013.
He is also an industry advisor to Deccan and North India section of RSC. Recently, he became six sigma certified white belt, black belt and master black belt practitioner.
He has become a BoS (Board of Studies) and BoG (Board of Governors) members of Institute of Science and Engineering, Jawaharlal Nehru Technological University, Hyderabad (JNTU-H) starting from December 2017. He is also serving as an International Advisory Board Member of European Journal of Organic Chemistry. He is a visiting faculty at Department of Chemistry, Delhi University, KNI Sultanpur, JNTUH campus and NIPER Hyderabad.
Aspen Oss B.V.
Having over 20 years of experience in supply chain with roles in global and strategic sourcing for large companies such as Philips and DSM, René is nowadays leading the procurement organization of Aspen Oss, the Netherlands, an API manufacturer with specialization in complex and HPAPIs. His focus lies on continuously developing the procurement organisation, adding value by connecting the business requirements with the suppliers’ capabilities in a compliant and agile way of working. The procurement team has a long-lasting experience in the sourcing of raw materials and has a network of suppliers on several continents, thereby ensuring full quality oversight, control, traceability and availability.
CDMO Division of Lubrizol Life Science Health (LLS Health)
Dr. Lee is responsible for product and business development along with providing strategic direction. Before joining LLS Health, Rob held senior management positions at Novavax, Inc., Lyotropic Therapeutics, Inc., and Imcor Pharmaceutical Co. He holds BSs in Biology and Chemistry from the University of Washington and a PhD in Physical Bioorganic Chemistry from the University of California, Santa Barbara. Rob has published more than three dozen articles and three five book chapters plus holds 11 issued patents and 15 provisional or PCT patent applications. He has over 30 years of experience in pharmaceutical research and development of both therapeutic drugs and diagnostic imaging agents. Rob maintains strong academic ties, including an appointment as Adjunct Associate Professor of Pharmaceutical Chemistry at the University of Kansas in the early 1990s, serving as a reviewer for both the International Journal of Pharmaceutics and Journal of Pharmaceutical Sciences, and serving on the Editorial Board for the Journal MOJ Bioequivalence & Bioavailability, The Scientific Pages of Nanotechnology, and The Journal of Analytical and Pharmaceutical Research.
BD Medical - Pharmaceutical Systems
Sagar Bejalwar's responsibilities include developing prefillable syringe solutions that most closely address drug manufacturer and clinician needs. Mr Bejalwar holds an MBA from Texas Christian University (Fort Worth, TX, US) and also a Bachelor’s degree in Electrical Engineering from the National Institute of Technology, India.
Sai Shankar is the Vice President, Global Digital Healthcare Systems at Aptar Pharma. Sai has 18 years of product development and business strategy experience in the pharmaceutical industry. He joined Aptar in April 2017, having had previous roles at Allergan and Sanofi, where he was Head of Packaging Development and also lead CMC teams. Sai has recently presented at international events, including Pharmapack in Paris, CPhi in Frankfurt, Innovative Drug Delivery Solutions Symposium in China and Nasal Drug Delivery in the UK.
Sarah Hardison is Head of Product, Regulatory at Clarivate Analytics. Prior to joining Clarivate, Sarah worked in Product and Portfolio Management in Life Sciences companies, helping to deliver to enable drug development and novel drug discovery. Sarah earned her PhD in Immunology at the University of Texas.
Education: - Ph.D. in Pharmacy, Tokyo University, 2010 Qualification: - Doctor of Pharmacy Experience: - 2018 – Current: Bachem Japan K.K., - 2009 – 2018: Meso Scale Diagnostics, LLC., Sato Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co. Ltd. - 1995 – 2009: Banyu Pharmaceutical Co., Ltd. Research Pharmacologist.
Friends Of Cancer Patients UAE
Dr. Sawsan A. S. Al Madhi has more than 18 years progressive leadership skills and experience in strategy, operations and
administration for the not-profit charitable sector. Currently working with one of the most reputable charities in the UAE as the Director General for Friends of Cancer Patients, Dr. Sawsan’s role is to supervise the continuing refinement and expansion of the organizational objectives which include:
providing high quality services, organizing fundraising activities,
developing ,planning and executing nationwide awareness programs and
campaigns through collaboration with a vast network of national and
international, governmental and private sector organizations.
Scott Watson is VP and Head of Commercial Operations at Benuvia Manufacturing. He also serves as Principal of The C=C Bond Group which provides strategic and tactical advisory consulting services to
pharmaceutical and biotechnology companies. Previously, Mr. Watson held sales and operational leadership positions at Eastman Chemical Company, Durect Corporation, DSM, and AMPAC Fine Chemicals. Since 2000, he has served as a Professor and Adjunct Professor at the University of Alabama at Birmingham.
Mr. Watson received an MBA from George Mason University and a BS in Chemistry from the US Naval Academy. He holds the Chartered Financial Analyst ® (CFA) designation.
Free University of Berlin
Sebastian Stolzenberg is a postdoctoral project leader at Free University of Berlin, holds a Physics Ph.D. from Cornell University, and is a former Fulbright Fellow. During his dissertation under Prof. Harel Weinstein in New York, he studied detailed molecular mechanisms of transmembrane proteins, whereas in Berlin under Prof. Frank Noé, he now
investigates with supercomputers at Oak Ridge National Laboratories molecular aspects of the adaptive immune system. He has recently developed a deep neural network (AI) software to predict immunogenicity of linear epitope and proteins.
Sharon Cunningham is co-founder of Shorla Pharma, an Irish specialty pharmaceutical company. A driven and compassionate company, Shorla Pharma have developed an innovative pipeline of oncology drugs focusing on women’s and children’s cancers. The company raised €7.5m in Series A funding in June 2020. Sharon was awarded the title of Ireland’s Best Young Entrepreneur 2019 and was included on a list of 50 people to look out for in 2020 by the Irish Times. She also won the prestigious Worldwide Association of MBA's Best Entrepreneurial Venture Award (Private Sector) 2020. In 2019 she led an international team to win the MIT-Harvard Medical School Healthcare Innovation Bootcamp Pitching Competition in Boston, US. Having graduated with an MBA from University College Dublin Smurfit School in 2015, Sharon went on to co-found Shorla Pharma with her former EirGen Pharma colleague, Orlaith Ryan. Sharon is also a PwC qualified Chartered Accountant and holds a BSc in Finance from University College Cork. She sits on the board of Irish Rule of Law International.
Dr. Shirley O’Dea co-founded Avectas in 2012 and is the company’s CSO, in addition to serving on the Board of Directors. She is charged with evaluating, overseeing and implementing both the internal and external scientific programs at Avectas. With a scientific career in cell biology extending over 25 years, prior to co-founding Avectas Shirley completed research fellowships at University of Edinburgh Medical School and also served as a Principal Investigator for several industry collaborations.
Sian Estdale is the Head of Scientific Affairs within Clinical Trials Testing Solutions at Covance where she has worked since 2002. Her expertise is in methodologies to support drug development of molecules, especially biologics from R & D to market in CMC and BioA and now patient care analysis. Previous to Covance, Sian was an academic, lecturing in Biomedical Sciences at Bradford and Sheffield Hallam Universities with 14 years research experience in diverse areas: recurrent miscarriage, ischemia-reperfusion and skin research. She has a PhD in organic chemistry.
Dr. Reddy's Laboratories Ltd.
Dr. Srividya Ramakrishnan heads Process Engineering (API) at Dr. Reddy’s Laboratories. She has a doctorate in Chemical Engineering from Princeton University, and worked at Unilever Research and Bristol-Myers Squibb in New Jersey prior to joining Dr. Reddy's in 2008. She is also an ASQ-certified Six Sigma Black Belt and has several patents and publications to her credit. She has actively participated in furthering Diversity & Inclusion initiatives at Dr. Reddy’s and has recently taken up an additional role as Chief Diversity Officer.
The Medicine Maker
Stephanie is the Editor of Texere Publishing’s The Medicine Maker and The Small Molecule Manufacturer brands, which focus on showcasing the pharma industry’s success stories and biggest points of contention. Stephanie has been writing about the trends and technologies shaping the industry for over a decade and has been involved with The Medicine Maker since its initial launch. She has a degree in Creative and Professional Writing and specializes in conveying the stories behind the science.
AMR Industry Alliance
Steve Brooks currently serves as an Advisor to the Antimicrobial Resistance (AMR) Industry Alliance, and chairs the Manufacturing Work Group of the Alliance. Prior to this engagement, Steve gained almost 37 years of pharmaceutical industry experience in the UK and the US with Pfizer in roles of increasing complexity, scope and responsibility. Steve has mentored many colleagues, formally and informally, developed and implemented major corporate programs and is a recognized EHS leader in the pharmaceutical industry.
A Chartered Biologist and GSK Senior Fellow with a Masters degree in Industrial Pharmacy and PhD in Pharmaceutics. Currently working in Pharmaceutical Development (PD), Terry has over 25 years experience in the pharmaceutical industry at GSK, spanning R&D and Commercial Supply. In addition to being a Team Leader within PD, Terry also leads a global group focused on age appropriate product development and is a member of a number of Paediatric focus groups within and external to GSK. Terry is passionate about age appropriate drug development and continues to actively research and collaborate with academia and other industry partners.
Dr. Thomas VanCott joined Paragon Gene Therapy following 14 years as the President and CEO of Advanced Bioscience Laboratories, Inc. (ABL), a contract manufacturing and laboratory research services company. Before joining ABL, he held several positions at the Henry M. Jackson Foundation for the Advancement of Military Medicine. He also served as a U.S. Army Captain in the Medical Service Corps at Walter Reed Army Institute of Research. Dr. VanCott received his PhD in Physical Chemistry from the University of Virginia and a B.S. degree in Chemistry from Dickinson College.
Noble, an Aptar Pharma company
Tim McLeroy is Executive Director of Marketing and Patient Services at Noble, an Aptar Pharma company, where he leads the development and execution of product and service launch initiatives, and directs Noble’s marketing strategies. Prior to Noble, Tim led the Nayzilam® launch for UCB’s U.S. Neurology Patient Value Unit and served as the stakeholder execution lead for UCB’s immunology business in the U.S., with work in biosimilar strategy.
Tom has worked at Hanway since 2018 leading a broad range of projects with medical and wellness (CBD) companies. He has particular interests in go-to-market strategies for companies looking to break into Europe as well as the intersection between technology and healthcare. Prior to Hanway Tom spent 8 years as a Management Consultant at Accenture and IQVIA, working with large pharma companies across Europe.
Victoria Morgan has been in the pharmaceutical industry for more than 25 years with extensive experience across primary and secondary care and the area of injection drug delivery products, such as primary packaging and combination products for vial, prefilled syringe systems, cartridges and devices.
Throughout her tenure at West, she has served in various functions across sales and marketing. Victoria spent more than 17 years in global sales roles followed by 3 years as Director of Segment Marketing, Biologics here at West, where she has responsibility for global biologics strategy development and implementation.
Yasemin is a Consultant in the European Thought Leadership team based in IQVIA’s London office. Her primary areas of focus are; trends in innovative launches, drug delivery and formulations as well as the oncology market with emphasis on commercial trends. She has presented and moderated panels on these subjects in a variety of conferences. Yasemin holds a Masters in Cancer Research and a Bachelor of Science degree in Biomedical Sciences both from Newcastle University. Prior to her role in Thought Leadership, Yasemin was part of the Real-World Insights – Global Oncology team where she worked on the co-ordination and set-up of reports focusing on various cancers.
Dr. Sharma has over 15 years of experience in applying and managing data science and machine learning approaches to solving complex problems in the healthcare space. Yugal was a scientist for the National Institutes of Health (NIH), focusing on developing early disease detection algorithms. Since NIH, Yugal helped found a technology startup, followed by a business consulting startup. More recently, he applied his background as a consultant working with commercial and federal agencies to help advance their data science strategies. He has published several scientific articles, as well co-authoring a book chapter on the mining of Electronic Health Records to detect disease signals.
He is currently the Sr. Director of Solutions for CAS Services which creates customized approaches for your unique scientific information challenges – from AI/ ML initiatives, to faster workflows, and novel approaches to unlock value out of scientific data. Yugal received his PhD in Biophysics from University of Cincinnati, where he graduated with honors.